Introduction
============

Dengue is one of the most important arthropod-borne diseases in the tropics and subtropics region of the world. It is a disease of public health concern in over 125 countries [@B1]. At least four dengue virus (DENV) serotypes; DENV-1, DENV-2, DENV-3, and DENV-4 are known to cause dengue. The virus is usually transmitted to human through bites of infected *Aedes* mosquitoes. Most who contracted dengue present with a mild self-limiting fever, dengue fever (DF). Only 1-2% of the infected person would present with the more severe form of the disease known as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). DHF is usually characterized by vascular leakage, marked thrombocytopenia and hemorrhagic manifestations while DSS is the progression of DHF accompanied with hypovolemic shock and hypotension [@B2], [@B3]. If not adequately treated, DHF and DSS could lead to death. At least 22,000 dengue deaths are reported annually [@B4].

To date, the pathogenesis of DHF/DSS remained not well understood. A number of hypotheses have been forwarded and these include the pathogenic effects of highly virulent variants of DENV [@B5] and the involvement of exaggerated host immune response [@B6]-[@B8]. Higher risk of contracting DHF/DSS in individuals with previous exposure to DENV has been well-documented [@B9], [@B10]. Evidences supporting the importance of antibody-dependent enhancement (ADE) of infection and T cell \'original antigenic sin\' in induction of severe dengue have been presented. Alteration in the cytokine and T helper (Th) cell responses in secondary DENV infection has been described in the pathogenesis of severe dengue [@B6], [@B7].

Most evidences suggesting either protective or pathological role of cytokines in severe dengue, however, have been derived mainly from the clinical and epidemiological studies. A number of studies for instance have reported higher serum levels of anti- and pro-inflammatory cytokines such as interleukin-1 beta (IL-1β), IL-2, IL-6, IL-8, IL-10, IL-13, IL-18 and tumor necrosis factor alpha (TNF-α) in DHF/DSS patients [@B11]-[@B14]. Other studies, however, revealed variations in the results as some did not find differences in the cytokine production. Several *in vitro* studies demonstrated that ADE in DENV infection induces IL-10 mediated immunosuppression with diminished production of antiviral nitric oxide (NO) and pro-inflammatory cytokines including IL-12, interferon gamma (IFN-γ) and TNF-α [@B15], [@B16], while other reports showed increased production of IL-10, IFN-α, and TNF-α [@B17].

The role of human genetics in determining susceptibility to infectious diseases has been reviewed [@B18]. Earlier studies in other diseases have shown that polymorphisms at the IL-10, IL-12B and TNF-α influence production of these cytokines [@B19]-[@B25] contributing to the varied individual immune response to stimuli. It is similarly postulated that these polymorphisms could also influence the cytokine response profile during early stage of DENV infection, leading to differences in the immune response pattern and thus the outcome of the disease. Here we investigated the possible influence of the IL-12B, IL-10 and TNF-α promoter polymorphisms in protection and/or predisposition to severe dengue.

Materials and Methods
=====================

Dengue patients and controls
----------------------------

The present study was approved by the University Malaya Medical Center (UMMC) Medical Ethics Committee (ethics committee/ IRB reference number: 611.10). A total of 282 clinically dengue-diagnosed patients from UMMC during the year 2006-2007 were retrospectively enrolled into the study (informed consents were not obtained from these patients). Clinical records and laboratory findings of the dengue patients were obtained and reviewed. Clinical classification of dengue as DF, DHF and DSS was performed according to the World Health Organization (WHO) 1997 guideline [@B2]. This was done as the clinical notes were all in accordance to the WHO 1997 guideline. Patients\' clotted blood samples were obtained from the Microbiology Laboratory Diagnostic Repository for genomic DNA extraction. The control group of this study consisted of 120 unrelated, gender and ethnicity-matched healthy volunteers tested negative for anti-dengue IgG antibodies. Their blood samples were obtained with written consents for genomic DNA extraction.

Detection of gene polymorphisms in IL-10 promoter gene, IL-12B and TNF-α promoter gene
--------------------------------------------------------------------------------------

Human genomic DNA was extracted from approximately 400 µl of pulverized clotted blood using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Genomic DNA was eluted in 200 µl of nuclease-free water and kept at -20ºC until needed.

The IL-12B 3\'UTR Taq I polymorphism (rs3212227) and the two single nucleotide polymorphisms (SNPs) of the IL-10 gene promoter at the position -592 (rs1800872) and -1082 (rs1800896) were genotyped using polymerase chain reaction (PCR) coupled with restriction fragment length polymorphisms (RFLP) [@B26], [@B27]. PCR amplification of IL-10 -592, -1082 and IL-12B 3\'UTR fragments were performed by adding 1 µl of extracted DNA into a volume of 24 µl reaction containing nuclease-free water, 1× GoTaq® Flexi Buffer (Promega, USA), 1.5 mM MgCl~2~, 0.2 mM dNTPs, 2.5 units of GoTaq® DNA Polymerase (Promega, USA), and 0.6 pmol of each forward and reverse primer (Table [1](#T1){ref-type="table"}). The PCR reactions for each fragment were performed at conditions summarized in Table [2](#T2){ref-type="table"}. Amplified IL-10 -592 and -1082 fragments were subsequently treated with 12 U of Rsal (Promega, USA) and 10 U of Mnl I (New England Biolabs, UK) at 37ºC for 1 hr and 1.5 hr, respectively. Amplified IL-12B 3\'UTR fragment was digested with 10 U of Taq I at 65ºC for 2 hr. The restriction patterns were examined by gel electrophoresis (Table [2](#T2){ref-type="table"}).

The IL-10 -819 SNP (rs1800871) was not genotyped as there is complete linkage disequilibrium between IL-10 -819 and -592 SNPs. Furthermore, PCR-RFLP genotyping results of IL-10 promoter SNPs in at least half of the samples was verified by nucleotide sequencing of the IL-10 promoter fragment amplified using primer FP-592 and RP-1082 (Table [1](#T1){ref-type="table"}). Sequencing was performed in one direction using the BigDye Terminator v3.1 Cycle Sequencing Kit on a capillary DNA sequencer 3730xl DNA analyser (Applied Biosystems, USA).

Allele-specific primers [@B21] were used to detect IL-12Bpro (CTCTAA/GC) polymorphisms (rs17860508) (Table [1](#T1){ref-type="table"}). PCR amplification of IL-12B promoter region was performed in a total volume of 25 µl PCR reaction containing nuclease-free water, 1× GoTaq® Flexi Buffer (Promega, USA), 1.5 mM MgCl~2~, 0.2 mM dNTPs, 2.5 units of GoTaq® DNA Polymerase (Promega, USA), 0.6 pmol of each forward and reverse primer (Table [1](#T1){ref-type="table"}) and the extracted DNA. The PCR conditions are summarized in Table [2](#T2){ref-type="table"}.

The TNF-α -308 SNP (rs1800629) was genotyped by using dual priming oligonucleotide (DPO) primer-based duplex PCR. The SNP specific DPO primers were designed based on the principle described earlier [@B28]; in each primer a single variation was located at the middle of 3\' segment for accurate discrimination. PCR amplification was performed in a total of 15 µl reaction containing nuclease-free water, 1× MyTaq Mix, 0.6 pmol of each primer G308R and A308F, 0.3 pmol of each primer G308F and A308R, and the extracted DNA. Genotyping of TNF-α -308 SNP were further validated in all samples by sequencing the 527 bp TNF-α promoter fragment amplified using primers TNFa-F 5\' GGCCTCAGGACTCAACACAGC 3\' and TNFa-R 5\' CTTGCTGAGGGAGCGTCTGC 3\'. Sequencing was performed bi-directionally with both forward and reverse primers using the BigDye Terminator v3.1 Cycle Sequencing Kit on a capillary DNA sequencer 3730xl DNA analyser (Applied Biosystems, USA). The TNF-α promoter SNPs at positions -238 (rs361525) and -376 (rs1800750) were identified from the sequencing data.

Statistical Analysis
--------------------

A Pearson Chi-square was used to determine whether the observed frequencies of gene polymorphism genotypes conformed to Hardy-Weinberg equilibrium expectations. The genotype and allele frequencies were compared between patient groups by using a chi-square or Fisher\'s exact test. A two-sided *p*value \<0.05 was considered to be statistically significant. The correlation between the polymorphism genotypes and dengue severity was assessed by the odds ratio (OR) with corresponding 95% confidence intervals (CIs). All statistical analysis was performed using IBM SPSS Statistics, version 21 (IBM Corporation, New York, United States) and GraphPad Prims 5.01 (GraphPad Software Inc, La Jolla, CA, USA).

Results
=======

Demographics, clinical presentations and laboratory findings of DF and DHF/DSS patients
---------------------------------------------------------------------------------------

In this study, 282 clinically diagnosed dengue patients were recruited. Using the WHO 1997 guideline, 86 patients were classified as DF, 182 were DHF and 14 were DSS. The median age of DF and DHF/DSS groups was 26 years (range 0.3-66 years) and 28 years (range 0.8-81 years), respectively. The proportion of male and female among DF patients was similar, while male showed preponderance among the DHF/DSS group (OR=2.0 \[95% CI=1.2-3.3\], p=0.01) (Table [3](#T3){ref-type="table"}). The ethnic composition of dengue patients was paralleled to that of the total dengue patients presented to UMMC, majority of which were Malay (52.5%), followed by Chinese (17.4%), Indian (17.0%) and other races (12.4%).

The clinical features and laboratory findings of the dengue patients are summarized in Table [3](#T3){ref-type="table"}. The presence of plasma leakage including ascites, pleural effusion and hemoconcentration distinguished DHF/DSS from DF (p\<0.001, Table [3](#T3){ref-type="table"}). Tachycardia and restlessness were only detected among the DHF/DSS patients. Presentation of abdominal pain, and hepatomegaly were also statistically associated with DHF/DSS patients in comparison to DF patients (p\<0.05). Vomiting, even though not statistically significant (OR=1.7 \[95% CI=0.98-2.9\], p\<0.07), was more frequent in DHF/DSS than in DF. On the other hand, thrombocytopenia (platelet count \<100×10^9^/L) and increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (\>1000IU/L) were statistically significant in DHF/DSS patients. Leucopenia was common in both DF and DHF/DSS groups.

Dengue virus infection was confirmed in 275 patients by either serology (anti-dengue IgM and/or anti-dengue IgG \[Standard Diagnosis Inc., Korea\]), dengue NS1 antigen detection (Bio-Rad Laboratories, France), or virus isolation. Dengue IgM was negative in 7 patients (5 DF patients, 2 DHF patients); there was no record of other complimentary tests in these patients. On the other hand, there was no record of laboratory dengue testing in 1 DHF patient.

Distribution of TNF-α, IL-12B and IL-10 gene promoter polymorphisms among DF, DHF/DSS and control groups
--------------------------------------------------------------------------------------------------------

Overall, genotyping of TNF-α, IL-12B and IL-10 gene promoter SNPs was successful in at least 98% (n=396) of the studied patients. The distributions of all gene alleles and genotypes were consistent to the Hardy-Weinberg equilibrium, except for the IL-12B 3\'UTR Taq I polymorphism in the control group. The frequencies of alleles and genotypes for the corresponding cytokine genes among the dengue patients and control group were summarized in Table [4](#T4){ref-type="table"}. The TNF-α -308A allele (OR=0.4 \[95% CI=0.2-0.8\], p=0.007) and -308GA genotype (OR=0.4 \[95% CI=0.2-0.8\], p=0.014) were distributed at decreased frequencies in the DHF/DSS patients in comparison to the control group. Among the DHF/DSS patients, the frequency of -308GG genotype was significantly higher compared to that of the control group (OR=2.5 \[95% CI=1.3-4.9\], p=0.007). In contrast, increased frequencies of -238A allele (OR=4.8 \[95% CI=1.1-21.0\], p=0.023) and -238GA genotype (OR=4.9 \[95% CI=1.1-21.9\], p=0.021) were found among DHF/DSS group in comparison to the control group. The rare -376A allele was detected at very low frequency (\<0.4%) among our study population and thus was excluded from further analysis. In our study, the -376 allele distribution did not differ between all groups.

The distributions of IL-12Bpro and IL-12B 3\'UTR gene variants were similar between all groups (Table [4](#T4){ref-type="table"}). The pro1 (CTCTAA) and pro2 (GC) alleles of IL-12Bpro were equally distributed among our study population; the pro1/pro2 heterozygote was the predominant genotype. Similarly, the AC heterozygous genotype of IL-12B 3\'UTR was predominant in our study population, followed by AA and CC genotypes (Table [4](#T4){ref-type="table"}). Further, all three IL-10 promoter SNPs at position -1082, -819 and -592 distributed similarly among all groups. The IL-10 promoter haplotypes were formed by the 3 bi-allelic SNPs (Table [5](#T5){ref-type="table"}). Our findings revealed three haplotypes in the population; ATA, ACC and GCC. Non-GCC haplotypes (ATA/ATA, ATA/ACC, or ACC/ACC) was predominant (81.2%) in the Malaysia population, while the GCC haplotypes (ATA/GCC, ACC/GCC, or GCC/GCC) was relatively less frequent. The GCC haplotypes, even though was not statistically significant, was more frequently distributed in DHF/DSS patients (20.5%) than in control group (13.6%) (Table [5](#T5){ref-type="table"}).

The distributions of the combined cytokine gene genotypes were summarized in Table [5](#T5){ref-type="table"}. In comparison to the control group, three combined genotypes were detected at significantly lower frequencies among the DHF/DSS patients: the TNF-α -308GA+AA/IL-10 non-GCC haplotypes (OR=0.3 \[95% CI=0.2-0.7\], p=0.002), the TNF-α -308GA+AA/IL-12Bpro homozygote (pro1/pro1+pro2/pro2) (OR=0.4 \[95% CI=0.2-1.0\], p=0.042), and the TNF-α -308GA+AA/IL-12B 3\'UTR AC (OR=0.3 \[95% CI=0.1-0.8\], p=0.026) (Table [5](#T5){ref-type="table"}). The distribution of these combined genotypes, however, was not different between DF and DHF/DSS or the control group.

A segregation analysis based on the gender of the study population was performed. No differences in genetic association in dengue severity were observed between the male and female. Association was found only with the combined genotype of IL-10 non-GCC/TNF-α -308GA/AA, where the genotype frequency was significantly decreased in the DHF/DSS patients in comparison to the control group, among male (OR=0.3 \[95% CI=0.1-0.9\], p=0.035) and female (OR=0.4 \[95% CI=0.2-0.9\], p=0.046). There was no significant difference detected in the distributions of other alleles, genotypes or combined genotypes between all groups.

Association between TNF-α, IL-12B and IL-10 gene promoter polymorphisms and clinical features of dengue
-------------------------------------------------------------------------------------------------------

No significant differences in the frequencies of gene polymorphisms between DF and DHF/DSS patients were observed in our study. Here, the dengue patient population was stratified based on the clinical presentations and analyzed for the distribution of gene polymorphisms. Our findings revealed gene associations between the TNF-α -308, IL-10 and IL-12B genotypes and the distinctive clinical presentations of DHF/DSS as shown in Table [6](#T6){ref-type="table"}. The association with thrombocytopenia was the most significant, in which the frequencies of TNF-α -308GA+AA genotypes, IL-12B 3\'UTR AC and the combination of genotypes IL-10 non-GCC haplotypes, IL-12B heterozygote (pro1/pro2) and TNF-α -308GA+AA were significantly reduced in those presenting thrombocytopenia (p\<0.05, Table [6](#T6){ref-type="table"}). Similar associations were also found between the similar genotypes with presentations including increased AST and ALT, hemoconcentration, hepatomegaly and abdominal pain prominent in severe dengue (Table [6](#T6){ref-type="table"}).

Discussion
==========

In this study, we investigated the association of selected cytokine gene polymorphisms in severe dengue. Our findings revealed a protective association of TNF-α -308A allele and -308GA genotype against DHF/DSS, while TNF-α -238A allele and -238GA genotype were associated with manifestation of severe dengue. Combination of TNF-α -308GA+AA genotype and IL-10 non-GCC haplotypes, IL-12B pro homozygotes (pro1/pro1, pro2/pro2) and IL-12B 3\'UTR AC were significantly correlated with protective effects against DHF/DSS. Findings from our study also supported a correlation between the cytokine gene polymorphisms and the clinical features associated with severe and fatal dengue [@B3].

TNF-α polymorphisms were found important in dengue. While the -308A allele has been related to enhanced TNF-α gene transcriptional activity [@B20], [@B25], the -238A allele has been shown to reduce the TNF-α gene expression [@B19]. Our findings showed a correlation between the high-expressing TNF-α alleles and protection against DHF/DSS, suggesting a possible protective role of TNF-α in the pathogenesis leading to severe dengue. Our findings, even though contradict earlier reports which showed association between increased plasma level of TNF-α and DHF/DSS [@B29], [@B30], are consistent with *in vitro* reports showing important role of TNF-α in suppresing DENV infection [@B15], [@B31]. The discrepancy in the observation between TNF-α in serum of DHF/DSS patients against that of *in vitro* results and in ours, is most likely because in the earlier, TNF-α is measured in patients who are already experiencing severe dengue where there are already massive pathological changes. In contrast, most DENV infections are either inapparent or subclinical [@B32], [@B33] suggesting effective control of virus infection early in the infection. While the antiviral immune response is early, most studies analyzed the cytokine production during dengue patients\' defervescence stage of infection [@B29], [@B30].

TNF-α modulates acute inflammatory response to bacterial or viral infections and has been shown to be involved in viral clearance and host defense against infections with West Nile virus [@B34], encephalomyocarditis virus [@B35], Hepatitis B virus [@B36] and Influenza virus [@B37]. In dengue, it has been shown that transient suppression of TNF-α production during the early period of ADE infection in THP-1 cells promoted the initiation of DENV replication [@B15]. Yet in another study, TNF-α at high and medium concentration was shown to inhibit DENV replication in human dendritic cells, a primary DENV target cells [@B31]. Our finding of high TNF-α producing alleles being the protective traits against development of DHF/DSS, hence, is in agreement with these reports suggesting that high TNF-α secretion phenotype is likely to confer protective effects against severe dengue perhaps by suppressing the DENV load during the early infection phase.

Correlation between TNF-α -308A allele and DHF has been reported earlier in patient population of Venezuela and Cuba [@B38], [@B39], but other studies did not find association in their group of patients [@B40]-[@B43]. A study in Mexico showed that the -238A allele was associated with protection of symptomatic dengue [@B41]. Similar to our findings, Vejbaesya *et al* identified the relation between the combined TNF-α -238A/lymphotoxin-alpha (LTA)-3 haplotype and DHF with secondary DENV infection [@B42]. The differences in results between the studies, however, may be due to the different populations examined. Perhaps there were enough similarities in the genetic background of Thais and Malaysians resulting in the consistent finding between the two populations in contrast to that performed in Venezuela and Mexico. In addition, limited sample size was noted in most of the earlier studies, in which the number of DHF patients used was less than 50 [@B38], [@B39], [@B41]. In contrast, the current study benefits from 196 well-characterized DHF/DSS subjects.

Elevated IL-12 serum level has been reported in DF patients and not in DHF/DSS patients [@B44], [@B45]. Two polymorphisms within the IL-12B gene, IL-12Bpro and IL-12B 3\'UTR Taq I polymorphism, were shown to influence IL-12p70 synthesis and may be functionally relevant in disease with an altered Th1 balance [@B22], [@B23], [@B46]-[@B48]. We showed here that the combined genotypes IL-12Bpro homozygote/TNF-α -308GA+AA and IL-12B 3UTR AC/TNF-α -308GA+AA were significantly associated with protective effects against DHF/DSS. The presence of the C allele in IL-12B 3\'UTR is associated with higher production of IL-12 [@B23], [@B24], [@B49] and the C allele has also been related to spontaneous viral clearance in Hepatitis C infection [@B50]. On the other hand, the IL-12Bpro homozygosity has been associated with a higher gene transcription and cytokine production than the IL-12Bpro heterozygote [@B22], [@B47], [@B51], [@B52] and the low expressing IL-12Bpro heterozygous confers risk to cerebral malaria (CM) [@B51]. The functional effect of the IL12B gene polymorphisms in response to DENV infection, however, requires further investigation.

Earlier studies showed that increased production of IL-10 in DHF patients was accompanied with suppressed secretion of IL-12 and TNF-α, impaired T cell proliferation and altered antiviral IFN response [@B53]. And the presence of IL-10 promoter -1082G allele is associated with higher levels of IL-10 production [@B54]. Studies in Venezuela and Cuba populations, however, reported contradicting results that the low IL-10 production-related ACC/ATA haplotypes was associated with DHF [@B38], [@B39]. No significant differences in the frequency of IL-10 gene variants between the DF and DHF/DSS patients and control group were noted in our study. The combination of low IL-10 producing non-GCC haplotypes and TNF-α -308GA+AA genotypes, however, was significantly correlated with protective effects against development of DHF/DSS. This finding supports the previous findings that high IL-10 production is associated with severe dengue [@B12], [@B15], [@B16]. It is envisage that naturally high production of IL-10, genetically regulated during the early phase of infection could result in unrestricted virus replication. This would lead to increase number of infected cells and tissues with subsequent over-production of inflammatory mediators which could then trigger vascular leakages [@B55], [@B56]. Incidentally, high virus load and prolonged viremia have been correlated with increased dengue severity [@B57], [@B58].

Our finding that possession of high TNF-α/low IL-10 genotypes is protective against thrombocytopenia and elevated AST is in agreement with previous reports that high serum level of IL-10 is associated with thrombocytopenia and raised liver enzymes in dengue patients [@B55], [@B59], [@B60]. At this point, however, there is no direct clinical or physiological role of TNF-α and IL-12 in the pathogenesis of thrombocytopenia or liver damage seen in the severe dengue apart from indirectly stimulating immune responses to reduce virus load hence reducing infection of the bone marrow and liver.

The current study is a retrospective case-control study. Lack of serial clinical and laboratory data of the dengue patients is among the limitations of the study. A prospective study is desired to enable investigation of the functional relationship between host genetics and the dynamics of virus load and host immune response at the early stage of DENV infection. These analyses, however, have been limited and are almost impossible as the dengue patients did not present to the medical centers until they developed symptoms and became sick. Biological data is needed to verify the functionality of gene polymorphisms with actual cytokine production during infection. These data would be useful for further understanding of the physiological relevance of the gene polymorphisms in the pathogenesis of DHF/DSS vis-à-vis protection against severe dengue. In the present study, we did not pursue this further due to the limitation of sample size especially for those gene alleles or genotypes which are rare in our population [@B61].

In conclusion, our study reports an association of the high producing TNF-α alleles and genotypes with protection against development of DHF/DSS. Combination of TNF-α -308GA+AA genotypes and IL-10 non-GCC haplotypes, IL-12Bpro homozygotes and IL-12B 3\'UTR AC are associated with protective effects against DHF/DSS. Our study also revealed a protective association between the genotypes and clinical features significant in DHF/DSS, which included thrombocytopenia and elevated liver enzymes. Efficient viral clearance at the early stage of infection in an environment of low IL-10 and high TNF-α could be the mechanism conferring protection against manifestation of severe dengue. Further evaluation, however, is needed to investigate the possibility of early treatment with TNF-α or anti-IL-10 antibody for the prevention against severe outcome of dengue.
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###### 

Primers for the detection of IL-10, IL12B and TNF-α gene polymorphisms.

  ----------------------------------------------------------------------------------------------------------------
  Gene Polymorphisms                    Genotyping Method     Primer Sequence (5\' → 3\')
  ------------------------------------- --------------------- ----------------------------------------------------
  IL10-C592A (rs 1800872)               PCR-RFLP              FP-592: CCTAGGTCACAGTGACGTGG\
                                                              RP-592: GGTGAGCACTACCTGACTAGC

  IL10-A1082G (rs 1800896)              PCR-RFLP              FP-1082: AGGTCCCTTACTTTGCTCTTACC\
                                                              RP-1082: CTCGYYGCAACCCAACTG

  IL12B 3\'UTR Taq I A/C (rs 3212227)   PCR-RFLP              FP1: ATTTGGAGGAAAAGTGGAAGA\
                                                              FP2: AATTTCATGTCCTTAGCCATA

  IL12B pro (rs 17860508)               PCR allele-specific   FP: GTCAATGGGCATTTGGCTCATATT ACC\
                                                              RP1: ATTGGTCCTTCTGTTTTGTCCTAA TGTGGGGGCCACATTAGAG\
                                                              RP2: TCTAATGTGGGGGCCACAGC

  TNF-α-G308A (rs 1800629)              DPO primer PCR        G308F: AGAAATGGAGGCAATAGGTTT TGAIIIIIATGGGG\
                                                              G308R: CTCTGCTGTCCTTGCTGAGIIIII GTCTGC\
                                                              A308F: GGCCTCAGGACTCAACACIIIIIT TCCCTC\
                                                              A308R: GGACCCTGGAGGCTGAAIIIIITC CTCA
  ----------------------------------------------------------------------------------------------------------------

###### 

PCR conditions and gel electrophoresis setting for the genotyping of IL-10, IL12B and TNF-α gene polymorphisms.

  Gene Polymorphisms     PCR Thermal Condition                                                                                  Gel electrophoresis
  ---------------------- ------------------------------------------------------------------------------------------------------ -----------------------------
  IL10-C592A             95ºC for 2 min, 35 cycles of 94ºC for 30 sec, 60ºC for 45 sec, 72ºC for 1 min, final 72ºC for 10 min   2.5% agarose gel
  IL10-A1082G            95ºC for 3 min, 40 cycles of 94ºC for 30 sec, 66ºC for 30 sec, 72ºC for 30 sec, final 72ºC for 2 min   4% MetaPhor^TM^ agarose gel
  IL12B-3UTR Taq I A/C   95ºC for 10 min, 35 cycles of 94ºC for 1 min, 54ºC for 1 min, 72ºC for 2 min, final 72ºC for 7 min     2.5% agarose gel
  IL12B pro              95ºC for 10 min, 35 cycles of 94ºC for 1 min, 54ºC for 1 min, 72ºC for 2 min, final 72ºC for 7 min     3.5% agarose gel
  TNF-α-G308A            95ºC for 2 min, 35 cycles of 94ºC for 30 sec, 66ºC for 1 min, 72ºC for 1 min, final 72ºC for 2 min     2.0% agarose gel

###### 

Demographic, clinical and laboratory findings of dengue patients.

  ---------------------------------------------------------------------------------------------------------------------
                                               DF (n=86)      DHF (n=196)     p-value (Fishers\')   OR; 95% CI
  -------------------------------------------- -------------- --------------- --------------------- -------------------
  Median age (range)                           26 (0.3-66)    28 (0.8-81)     0.506                 

  Gender (Male:Female)                         39:47          122:74          0.009                 1.99; 1.19-3.32

  Race (Malay:Chinese:Indian:Others)           47:17:11:11\   101:32:37:24\                         
                                               55:20:13:13%   52:17:19:12%                          

  Symptoms and signs                           n (%)          n (%)                                 

  Headache                                     51 (59.3)      121 (61.7)      0.694                 

  Retro-orbital pain                           13 (15.1)      27 (13.8)       0.853                 

  Abdomial pain                                28 (32.6)      98 (50.0)       0.009                 2.03; 1.19-3.45

  Rash                                         50 (58.1)      106 (54.1)      0.606                 

  Myalgia                                      75 (87.2)      156 (79.6)      0.188                 

  Arthralgia                                   39 (45.3)      78 (39.8)       0.434                 

  Vomiting                                     52 (60.5)      141 (71.9)      0.070                 1.68; 0.98-2.86

  Diarrhea                                     38 (44.2)      107 (54.6)      0.122                 

  Bleeding manifestations                      49 (57.0)      119 (60.7)      0.601                 

  Ascites                                      0 (0.0)        152 (77.6)      \<0.001               573.1; 34.84-9427

  Pleural effusion                             0 (0.0)        129 (65.8)      \<0.001               339.3; 20.70-5561

  Hepatomegaly                                 19 (22.1)      99 (50.5)       \<0.001               3.60; 2.01-6.43

  Lethargy                                     19 (22.1)      62 (31.6)       0.117                 

  Giddiness                                    25 (29.1)      57 (29.1)       1.000                 

  Shortness of breath                          4 (4.7)        18 (9.2)        0.233                 

  Tachycardiac                                 0 (0.0)        9 (4.6)         0.061                 

  Restless                                     0 (0.0)        10 (5.1)        0.035                 9.85; 0.57-170.10

  Laboratory Findings                                                                               

  Hemoconcentration (hematocrit ≥ 20%)         0 (0.0)        85 (43.4)       \<0.001               131.5; 8.04-2151

  Thrombocytopenia (\< 100 × 10^9^/L)          78 (90.7)      193 (98.5)      0.009                 4.95; 1.45-16.91

  Decreased white cell count (\< 4000/mm^3^)   71 (82.6)      144 (73.5)      0.128                 

  Increased AST (\> 1000IU/L)                  58 (67.4)      170 (86.7)      0.003                 2.71; 1.44-5.08

  Increased ALT (\> 1000IU/L)                  47 (54.7)      149 (76.0)      0.002                 2.41; 1.39-4.18
  ---------------------------------------------------------------------------------------------------------------------

Dengue fever (DF); Dengue hemorrhagic fever (DHF); Alanine aminotransferase (ALT); Aspartate aminotransferase (AST); Odds ratio (OR); Confidence intervals (CI)

###### 

Frequency of IL-10, IL12B and TNF-α gene polymorphism genotypes among the dengue patients and healthy control group.

  Gene                           DF n (%)     DHF n (%)       Control n (%)
  ------------ ----------------- ------------ --------------- ---------------
  IL12B                                                       
  Allele       IL12B pro1        82 (47.7)    177 (45.4)      104 (43.3)
               IL12B pro2        90 (52.3)    213 (54.6)      136 (56.7)
  Genotype     IL12B pro1/pro1   16 (18.6)    40 (20.5)       20 (16.7)
               IL12B pro1/pro2   50 (58.1)    97 (49.7)       64 (53.3)
               IL12B pro2/pro2   20 (23.3)    58 (29.7)       36 (30.0)
  IL12B-3UTR                                                  
  Allele       A                 98 (57.0)    232 (59.8)      143 (61.6)
               C                 74 (43.0)    156 (40.2)      89 (38.4)
  Genotype     AA                26 (30.2)    66 (34.0)       38 (32.8)
               AC                46 (50.5)    100 (51.5)      67 (57.8)
               CC                14 (16.3)    28 (14.4)       11 (9.5)
  IL10-1082                                                   
  Allele       G                 21 (12.2)    42 (10.8)       16 (6.8)
               A                 151 (87.8)   348 (89.2)      220 (93.2)
  Genotype     GG                1 (1.2)      1 (0.5)         0 (0.0)
               AG                17 (19.8)    40 (20.5)       16 (13.6)
               AA                68 (79.1)    154 (79.0)      102 (86.4)
  IL10-819                                                    
  Allele       C                 61 (35.5)    132 (34.2)      74 (31.1)
               T                 111 (64.5)   254 (65.8)      164 (68.9)
  Genotype     CC                13 (15.1)    26 (13.5)       13 (10.9)
               CT                35 (40.7)    80 (41.5)       48 (40.3)
               TT                38 (44.2)    87 (45.1)       58 (48.7)
  IL10-592                                                    
  Allele       C                 61 (35.5)    132 (34.2)      74 (31.1)
               A                 111 (64.5)   254 (65.8)      164 (68.9)
  Genotype     CC                13 (15.1)    26 (13.5)       13 (10.9)
               CA                36 (41.9)    81 (42.0)       48 (40.3)
               AA                37 (43.0)    86 (44.6)       58 (48.7)
  TNFa-376                                                    
  Allele       G                 169 (99.4)   388 (99.5)      240 (100.0)
               A                 1 (0.6)      2 (0.5)         0 (0.0)
  Genotype     GG                84 (98.8)    193 (99.0)      120 (100.0)
               GA                1 (1.2)      2 (1.0)         0 (0.0)
               AA                0 (0.0)      0 (0.0)         0 (0.0)
  TNFa-308                                                    
  Allele       G                 159 (92.4)   373 (95.6)^a^   216 (90.0)
               A                 13 (7.6)     17 (4.4)^b^     24 (10.0)
  Genotype     GG                74 (86.0)    178 (91.3)^c^   97 (80.8)
               GA                11 (12.8)    17 (8.7)^d^     22 (18.3)
               AA                1 (1.2)      0 (0.0)         1 (0.8)
  TNFa-238                                                    
  Allele       G                 164 (96.5)   375 (96.2)^e^   238 (99.2)
               A                 6 (3.5)      15 (3.8)^f^     2 (0.8)
  Genotype     GG                80 (94.1)    180 (92.3)^g^   118 (98.3)
               GA                4 (4.7)      15 (7.7)^h^     2 (1.7)
               AA                1 (1.2)      0 (0.0)         0 (0.0)

^a^Increased in DHF in comparison to control (p=0.007, OR=2.44, 95% CI=1.28-4.64)

^b^Decreased in DHF in comparison to control (p=0.007, OR=0.41, 95% CI=0.22-0.78)

^c^Increased in DHF in comparison to control (p=0.009, OR=2.48, 95% CI=1.27-4.87)

^d^Decreased in DHF in comparison to control (p=0.014, OR=0.43, 95% CI=0.22-0.84)

^e^Decreased in DHF in comparison to control (p=0.023, OR=0.21, 95% CI=0.05-0.93)

^f^Increased in DHF in comparison to control (p=0.023, OR=4.76, 95% CI=1.08-21.01)

^g^Decreased in DHF in comparison to control (p=0.021, OR=0.20, 95% CI=0.05-0.90)^h^Increased in DHF in comparison to control (p=0.021, OR=4.92, 95% CI=1.10-21.90)

###### 

Combination of IL-10, IL12B and TNF-α gene polymorphisms among the dengue patients and control population.

  Gene                                               DF n (%)    DHF n (%)     Control n (%)
  -------------------------------------------------- ----------- ------------- ---------------
  IL10 haplotypes                                                              
  Non-GCC (ATA/ATA, ACC/ACC, ATA/ACC)                68 (79.1)   154 (79.0)    102 (86.4)
  Heterozygous (ATA/GCC, ACC/GCC)                    17 (19.8)   40 (20.5)     16 (13.6)
  Homozygous GCC                                     1 (1.2)     1 (0.5)       0 (0.0)
  TNFa-308/IL10 haplotypes                                                     
  -308GG/IL-10 Non-GCC (ATA/ACC, ACC/ACC, ATA/ACC)   58 (68.2)   139 (71.6)    79 (66.9)
  -308GG/IL-10 GCC (ATA/GCC, ACC/GCC, GCC/GCC)       15 (17.6)   38 (19.6)     16 (13.6)
  -308GA+AA/IL-10 Non-GCC                            9 (10.6)    14 (7.2)^a^   23 (19.5)
  -308GA+AA/IL-10 GCC                                3 (3.5)     3 (1.5)       0 (0.0)
  IL12B/IL10 haplotypes                                                        
  (pro1/pro2)/ IL-10 Non-GCC                         40 (47.1)   71 (36.6)     54 (45.8)
  (pro1/pro2)/ IL-10 GCC                             9 (10.6)    26 (13.4)     9 (7.6)
  (pro1/pro1+pro2/pro2)/IL-10 Non-GCC                27 (31.8)   82 (42.3)     48 (40.7)
  (pro1/pro1+ pro2/pro2)/IL-10 GCC                   9 (10.6)    15 (7.7)      7 (5.9)
  IL12B-3UTR/IL10 haplotypes                                                   
  3UTR AA/IL-10 Non-GCC                              18 (20.9)   50 (25.8)     30 (26.3)
  3UTR AA/IL-10 GCC                                  8 (9.3)     16 (8.2)      6 (5.3)
  3UTR (AC+CC)/IL-10 Non-GCC                         50 (58.1)   103 (53.1)    69 (60.5)
  3UTR (AC+CC)/IL-10 GCC                             10 (11.6)   25 (12.9)     9 (7.9)
  IL12B/TNFa-308                                                               
  (pro1/pro2)/-308GG                                 43 (50.6)   89 (45.9)     54 (45.0)
  (pro1/pro2)/-308GA+AA                              6 (7.1)     8 (4.1)       10 (8.3)
  (pro1/pro1+pro2/pro2)/-308GG                       30 (35.3)   88 (45.4)     43 (35.8)
  (pro1/pro1+pro2/pro2)/-308GA+AA                    6 (7.1)     9 (4.6)^b^    13 (10.8)
  (pro1/pro1)/-308GG                                 14 (16.5)   36 (18.6)     15 (12.5)
  (pro1/pro1)/-308GA+AA                              2 (2.4)     4 (2.1)       5 (4.2)
  (pro2/pro2)/-308GG                                 16 (18.8)   52 (26.8)     28 (23.3)
  (pro2/pro2)/-308GA+AA                              4 (4.7)     5 (2.6)       8 (6.7)
  IL12B-3UTR/TNFa-308                                                          
  3UTR AA/-308GG                                     24 (27.9)   60 (30.9)     32 (27.6)
  3UTR AA/-308GA+AA                                  2 (2.3)     6 (3.1)       6 (5.2)
  3UTR AC/-308GG                                     39 (45.3)   93 (47.9)     55 (47.4)
  3UTR AC/-308GA+AA                                  7 (8.1)     7 (3.6)^c^    12 (10.3)
  3UTR CC/-308GG                                     11 (12.8)   24 (12.4)     7 (6.0)
  3UTR CC/-308GA+AA                                  3 (3.5)     4 (2.1)       4 (3.4)

^a^Decreased in DHF in comparison to control (p=0.002, OR=0.32, 95% CI=0.16-0.65)

^b^Decreased in DHF in comparison to control (p=0.042, OR=0.40, 95% CI=0.17-0.97)

^c^Decreased in DHF in comparison to control (p=0.026, OR=0.32, 95% CI=0.12-0.85)

###### 

Associations between gene polymorphisms and clinical features of dengue.

                                                           Fisher\'s Test                
  ------------------- ------------------------------------ ---------------- ------------ ---------
  Clinical Features   Gene Polymorphisms                   OR               95% CI       p value
  Hemoconcetration    IL12B-3UTR AA                        1.84             1.08-3.15    0.026
                      IL12B-3UTR AC                        0.54             0.32-0.92    0.025
                      IL12B-3UTR AC+CC                     0.54             0.32-0.93    0.026
                      IL12B-3UTR AA/TNF-α -308GG           1.94             1.13-3.35    0.022
                      IL12B-3UTR (AC+CC)/TNF-α -308GA+AA   0.24             0.05-1.04    0.045
  Thrombocytopenia    TNF-α -308GG                         7.29             2.15-24.75   0.004
                      TNF-α -308GA                         0.20             0.05-0.70    0.023
                      TNF-α -308GA+AA                      0.14             0.04-0.47    0.004
                      TNF-α -308GA+AA/IL-10 Non-GCC        0.10             0.03-0.35    0.001
                      IL12B-3UTR AA                        13.10            0.77-223.9   0.010
                      IL12B-3UTR AC                        0.21             0.04-0.96    0.037
                      IL12B-3UTR AA/TNF-α -308GG           11.45            0.67-195.8   0.021
                      IL12B-3UTR AC/TNF-α -308GA+AA        0.08             0.02-0.30    0.002
                      IL12B-3UTR (AC+CC)/TNF-α -308GA+AA   0.09             0.03-0.32    \<0.001
                      IL12B-3UTR (AC+CC)/IL-10 Non-GCC     0.10             0.01-0.78    0.007
                      IL12B (pro1+pro2)/TNF-α -308GA+AA    0.08             0.02-0.30    0.002
                      IL12B (pro1+pro2)/IL-10 Non-GCC      0.20             0.05-0.75    0.014
  Increased AST       TNF-α -308GG                         2.72             1.18-6.29    0.022
                      TNF-α -308GA                         0.35             0.15-0.81    0.018
                      TNF-α -308GA+AA                      0.37             0.16-0.85    0.022
                      TNF-α -308GA+AA/IL-10 Non-GCC        0.38             0.15-0.95    0.046
                      IL12B (pro1/pro2)/TNF-α -308GA+AA    0.27             0.09-0.82    0.026
                      IL12B-3UTR AC/TNF-α -308GA+AA        0.20             0.07-0.59    0.005
  Increased ALT       TNF-α -308GG                         2.92             1.34-6.38    0.009
                      TNF-α -308GA                         0.32             0.14-0.70    0.007
                      TNF-α -308GA+AA                      0.34             0.16-0.75    0.009
                      IL12B (pro1/pro2)                    0.58             0.34-0.99    0.048
                      IL12B (pro1/pro1+pro2/pro2)          1.72             1.01-2.91    0.048
                      IL12B (pro1/pro2)/TNF-α -308GA/AA    0.29             0.10-0.88    0.032
                      IL12B-3UTR AC/TNF-α -308GA/AA        0.21             0.07-0.66    0.006
  Hepatomegaly        IL12B (pro1/pro1)                    2.24             1.24-4.06    0.010
                      IL12B (pro1/pro1)/TNF-α -308GG       2.08             1.12-3.86    0.026
  Abdominal Pain      IL12B (pro1/pro2)/TNF-α -308 GA/AA   0.20             0.04-0.92    0.026
                      IL12B-3UTR AC/TNF-α -308 GA/AA       0.20             0.04-0.91    0.026

Alanine aminotransferase (ALT); Aspartate aminotransferase (AST); Odds ratio (OR); Confidence intervals (CI).

[^1]: Conflict of Interest: The authors have declared that no competing interest exist.
